Skip to main content

VRCA

Stock
Health Care
Biotechnology

Performance overview

VRCA Price
Price Chart

Forward-looking statistics

Beta
2.13
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Company info

SectorHealth Care
IndustryBiotechnology
Employees65
Market cap$347.0M

Fundamentals

Enterprise value$61.9M
Revenue$7.2M
Revenue per employee
Profit margin63.79%
Debt to equity-2.28

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.14
Dividend per share
Revenue per share$0.11
Avg trading volume (30 day)$409K
Avg trading volume (10 day)$836K
Put-call ratio

Macro factor sensitivity

Growth-1.1
Credit+9.5
Liquidity+0.9
Inflation-3.6
Commodities-3.9
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio-1.20
Price to sales9.10
P/E Ratio-1.20
Enterprise Value to Revenue8.62
Price to book-3.98

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend day

News

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.38 per share a year ago.

Zacks Investment Research (May 13, 2025)
Why Verrica Pharma Shares Are Plunging Today

The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application for VP-102 for molluscum contagiosum. The only deficiency listed in the CRL was related to the deficiencies identified at a general reinspection.

Benzinga (May 25, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free